Skip to content

Krystal Biotech

US · KRYS #1515 by market cap Listed 2017
308.89 -6.93 -2.19%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 306.20 -3.05%
After-hours 308.85 -0.01%
378.15293.21308.892026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on KRYS?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +21.5% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 10.3% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall A-

The radar needs all six factors. Available grades are shown below.

Valuation D-

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 42.0x Better than 12%
Forward P/E 32.4x Better than 16%
Price / Sales 19.2x Better than 6%
P/E vs own 5-yr range 68th pctl Better than 40%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability A+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 94.1% Better than 98%
Operating margin 41.5% Better than 96%
Net margin 52.6% Better than 97%
Return on equity 18.9% Better than 76%
Return on invested capital 16.8% Better than 85%
Momentum B+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -10.9% Better than 49%
6-month return 3.2% Better than 62%
12-month return (ex latest month) 46.9% Better than 82%
Distance below 52-week high 19.3% Better than 62%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 10.0x Better than 93%
Debt to assets 0.7% Better than 95%
Interest coverage -45.6x Better than 7%
Free cash flow / net income 92.2% Better than 33%
Analyst View B+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 27.3% Better than 44%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W +1.20%
1M -5.08%
3M -8.35%
6M +2.26%
YTD +25.29%
1Y +51.25%
3Y +194.80%
5Y +489.82%

Key statistics

Price & volume

Prev close
315.82
Open
313.38
Day range
308.22 - 321.27
Avg price
312.40
Volume
286.70K
Turnover
89.57M
Amplitude
4.13%
52-week range
212.02 - 382.54

Valuation

P/E
45.16
P/E (TTM)
41.97
P/B
6.38
EPS
6.84
Net profit
202.69M
Net assets
1.44B

Share structure

Market cap
9.15B
Float cap
7.31B
Shares out
29.63M
Float shares
23.66M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2017-09-20
52-week range 57% of range
212.02 382.54

19.3% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-15.04M net over the window

Short interest

Shares short
3.04M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Krystal Biotech (KRYS)?

Krystal Biotech last traded at 308.89. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Krystal Biotech's market cap?

About 9.15B.

What is the P/E ratio of Krystal Biotech?

The trailing twelve-month P/E is 41.97, above its own 5-year average of 29.75 — toward the top of its historical range (68.34% percentile). See the Valuation tab for the full history.

Does Krystal Biotech pay a dividend?

Krystal Biotech does not currently pay a regular dividend.

Is Krystal Biotech a buy according to analysts?

The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 393.17, which implies 27.3% upside from the current price. This is not investment advice.

What is Krystal Biotech's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Krystal Biotech a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Krystal Biotech discussion 0 comments

Add a comment